Coca-Cola’s Costa Coffee Sale Faces Uncertainty as Talks With TDR Capital Hit Snag 
Azul Airlines Wins Court Approval for $2 Billion Debt Restructuring and New Capital Raise 
Air Force One Delivery Delayed to 2028 as Boeing Faces Rising Costs 
Trello Outage Disrupts Users as Access Issues Hit Atlassian’s Work Management Platform 
SpaceX Insider Share Sale Values Company Near $800 Billion Amid IPO Speculation 
SpaceX Begins IPO Preparations as Wall Street Banks Line Up for Advisory Roles 
Trump Sues BBC for Defamation Over Edited Capitol Riot Speech Clip 
Woolworths Faces Fresh Class Action Over Alleged Underpayments, Shares Slide 
Nvidia Weighs Expanding H200 AI Chip Production as China Demand Surges 
United Airlines Tokyo-Bound Flight Returns to Dulles After Engine Failure 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
iRobot Files for Chapter 11 Bankruptcy Amid Rising Competition and Tariff Pressures 
Korea Zinc to Build $7.4 Billion Critical Minerals Refinery in Tennessee With U.S. Government Backing 
Biren Technology Targets Hong Kong IPO to Raise $300 Million Amid China’s AI Chip Push 
Korea Zinc Plans $6.78 Billion U.S. Smelter Investment With Government Partnership 
EU Signals Major Shift on 2035 Combustion Engine Ban Amid Auto Industry Pressure 
HSBC’s $13.6 Billion Take-Private Offer for Hang Seng Bank Gains Board Backing 
BASEL, Switzerland, Jan. 21, 2016 -- GSK (GlaxoSmithKline) informed Basilea today that it has elected to discontinue its U.S. alitretinoin program. Global rights to Toctino (alitretinoin) were transferred to Stiefel, a GSK company, in July 2012. Basilea has the option to re-acquire the U.S. alitretinoin rights. GSK continues to commercialize Toctino in its current markets.
About Basilea
Basilea Pharmaceutica Ltd. is a biopharmaceutical company developing products that address increasing resistance and non-response to current treatment options in the therapeutic areas of bacterial infections, fungal infections and cancer. The company uses the integrated research, development and commercial operations of its subsidiary Basilea Pharmaceutica International Ltd. to discover, develop and commercialize innovative pharmaceutical products to meet the medical needs of patients with serious and potentially life-threatening conditions. Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland and listed on the SIX Swiss Exchange (SIX: BSLN). Additional information can be found at Basilea's website www.basilea.com.
Disclaimer
This communication expressly or implicitly contains certain forward-looking statements concerning Basilea Pharmaceutica Ltd. and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd. is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
For further information, please contact:
| Media Relations | Investor Relations |
|
Peer Nils Schröder, PhD Head Public Relations & Corporate Communications +41 61 606 1102 [email protected] |
Barbara Zink, PhD, MBA Head Corporate Development +41 61 606 1233 [email protected] |
This press release can be downloaded from www.basilea.com.
Press release (PDF) http://hugin.info/134390/R/1980584/725577.pdf
HUG#1980584
